Pirfenidone, a novel anti-fibrotic agent, provides higher benefit for idiopathic pulmonary fibrosis (IPF) patients with better pulmonary function

被引：0
|
作者：
Ebina, M.
Kimura, Y.
Ohta, H.
Hisata, S.
Tamada, T.
Nukiwa, T.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2010年 / 181卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3988
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SYSTEMIC ANTI-FIBROTIC EFFECTS OF PIRFENIDONE IN PRECLINICAL STUDIES AND CLINICAL ACTIVITY IN IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Kossen, Karl
    Schaefer, C. J.
    Bradford, W. Z.
    Seiwert, S. D.
    INFLAMMATION RESEARCH, 2012, 61 : S5 - S5
  • [2] Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Hostettler, Katrin
    Papakonstantinou, Eleni
    Klagas, Ioannis
    Bonovolias, Ioannis
    Sun, Qingzhu
    Tamm, Michael
    Lambers, Christopher
    Roth, Michael
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [3] Characteristics Of Patients With Idiopathic Pulmonary Fibrosis (ipf) Receiving Approved Anti-Fibrotic Therapies In The Us
    Gamerman, V.
    Salisbury, M.
    Culver, D.
    Leonard, T.
    Neely, M. L.
    Yow, E.
    Conoscenti, C. S.
    Palmer, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [4] ELIGIBILITY FOR ANTI-FIBROTIC TREATMENT IN IDIOPATHIC PULMONARY FIBROSIS (IPF) DEPENDS ON THE PREDICTIVE EQUATION USED IN PULMONARY FUNCTION TESTING
    Burgess, Andrew
    Goon, Ken
    Attia, John
    Palazzi, Kerrin
    Brannan, John
    Grainge, Christopher
    RESPIROLOGY, 2017, 22 : 46 - 46
  • [5] Clinical Characteristics of Progressive Pulmonary Fibrosis of Idiopathic Pulmonary Fibrosis Patients Who Receive Anti-fibrotic Agent
    Kishaba, T.
    Nagano, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [6] PULMONARY HYPERTENSION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS ON ANTI-FIBROTIC TREATMENT WITH PIRFENIDONE OR NINTEDANIB: CLINICAL EVALUATION AND PROGNOSTIC IMPACT
    Stornelli, Silvia Romana
    Lacedonia, Donato
    Scioscia, Giulia
    Simone, Filomena
    Lepore, Giorgia
    Sabato, Roberto
    Giganti, Giulio
    Ciliberti, Gianluca
    Barbaro, Maria Pia Foschino
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [7] A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
    Shah, Parth, V
    Balani, Prachi
    Lopez, Angel R.
    Nobleza, Chelsea Mae N.
    Siddiqui, Mariah
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (01)
  • [8] Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis
    Sugino, Keishi
    Ono, Hirotaka
    Saito, Mikako
    Ando, Masahiro
    Tsuboi, Eiyasu
    PLOS ONE, 2024, 19 (06):
  • [9] An Evaluation of 116 patients with Idiopathic Pulmonary Fibrosis (IPF) commenced on anti-fibrotic treatment therapies (Pirfenidone and Nintedanib) from Jan 2019 to June 2021
    Bowen, B. R.
    Henry, M. T.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 5) : 162 - 162
  • [10] Ptpn11 Is A Novel Anti-Fibrotic Gene In Idiopathic Pulmonary Fibrosis
    Tzouvelekis, A.
    Cardenas, C. Lacks Lino
    Yu, G.
    Sakamoto, K.
    DeIuliis, J.
    Wyllie, A.
    Ahangari, F.
    Woolard, T.
    Heather, L.
    Herazo-Maya, J. D.
    Kaminski, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
12345